Competitive Advantage Period (CAP)
The Competitive Advantage Period (CAP) is the estimated number of years over which a firm is expected to earn returns on invested capital above its cost of capital before competition erodes the excess returns to zero — a critical variable in determining a company's intrinsic value.
All businesses, in theory, face competitive pressure that eventually drives returns on capital down towards the cost of capital. The CAP is the duration for which a specific business can resist that gravitational pull. A company with a 20-year CAP and a ROIC of 25 percent against a WACC of 12 percent is fundamentally worth far more than an identical current cash flow from a business with a 3-year CAP.
The concept was formalised by Alfred Rappaport in 'Creating Shareholder Value' and further developed by Michael Mauboussin in 'Expectations Investing'. In practice, analysts rarely model the CAP as a single point estimate. Instead, they typically model two or three scenarios — bear, base, and bull — each with different fade rates and CAP assumptions, then assign probabilities to derive a probability-weighted intrinsic value.
Fade rate refers to how quickly ROIC converges towards WACC after the CAP ends. A business with deep structural advantages may have a slow fade, maintaining above-WACC returns for a few years after the formal CAP ends. A business in a commoditising industry may fade quickly. Empirical studies of US listed companies suggest median CAPs of around 7 to 10 years, with only the strongest franchise businesses maintaining advantages beyond 15 years.
For Indian listed companies, several sectors have shown long CAPs historically: private sector banking franchises with strong CASA deposits and low credit cost cultures (HDFC Bank historically), consumer goods businesses with entrenched rural distribution (Hindustan Unilever, Britannia), and speciality chemicals companies with complex, custom-developed processes. Sectors with short CAPs tend to include commodity metals, commodity chemicals, and generic pharmaceutical formulators facing Chinese competition.
Estimating CAP requires both quantitative input (trend in ROIC, intensity of competition entering the industry) and qualitative judgement (whether the moat source is durable). Overestimating CAP is one of the most common valuation errors in bull markets, where optimism leads analysts to pencil in 20-year advantages for businesses that turn out to face disruption within five.